NASDAQ$SKIN
SkinHealth Systems Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported record first quarter results and updated fiscal 2021 outlook.
The Beauty Health Company reported a strong first quarter with net sales of $47.5 million, a 46% increase year-over-year. The company's performance was driven by strong sales in both delivery systems and consumables, and they have updated their top-line guidance for 2021 to approximately $200 million.
- Q1 net sales reached $47.5 million, up 46% from Q1 2020.
- Delivery system sales increased to $25.6 million, compared to $14.1 million in Q1 2020.
- Consumables sales increased to $21.9 million, compared to $18.5 million in Q1 2020.
- Q1 operating income was $2.4 million, a significant improvement from the $7.3 million operating loss in Q1 2020.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$47.5M
Revenue by segment
Beauty Health · $47.5M total across 2 segments · Q1 2021
- Delivery Systems$25.6M+81.6%53.9%
- Consumables$21.9M+18.4%46.1%
Forward guidance
For fiscal year 2021, the company expects net sales of approximately $200 million, adjusted EBITDA of approximately $25 million, and up to $15 million in capital expenditures.
Tailwinds
- Net sales of approximately $200 million.
- Adjusted EBITDA of approximately $25 million.
- Up to $15 million of capital expenditures.
- Expected results from the anticipated acquisition of certain distributors in the first half of 2021.
- Assumes a largely reopened global market.
Headwinds
- Subject to risks and uncertainties disclosed in filings with the Securities and Exchange Commission.
- Does not take into account the impact of any unanticipated developments in our business or changes in our operating environment.
- Does not take into account any unannounced acquisitions, dispositions or unannounced financings during 2021.
- Potential risk for further market closures from new COVID-19 strains.
- Uneven global rollout of the vaccines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro